SNAP-8 peptide: what it is, what the research shows and what is unknown

SNAP-8 is a cosmetic peptide made of eight amino acids with an acetyl group on one end and an amide on the other. Its ingredient name is acetyl octapeptide-3, some older labels use acetyl octapeptide-1 for the same material, and the trade name is written SNAP-8, SNAP 8 or SNAP8. It is a member of the family of so-called neurotransmitter-inhibitor peptides, a category that a 2009 review of topical anti-ageing peptides set alongside signal peptides such as Matrixyl, enzyme-inhibitor peptides and carrier peptides such as GHK-Cu ^[8].

The design comes from the hexapeptide Argireline (acetyl hexapeptide-8, also called acetyl hexapeptide-3), which was reported in 2002 by a group working with the Spanish ingredient company Lipotec. That paper described a rational design programme that produced a peptide copying the N-terminal end of SNAP-25, one of the three proteins that form the SNARE complex nerve cells need to release neurotransmitters ^[1]. SNAP-8 is the same sequence with two extra amino acids, alanine and aspartate, added at the C-terminal end. The manufacturer’s literature presents it as a more potent successor to Argireline, but that comparison has not been published in a peer-reviewed journal.

Two very different products carry the SNAP-8 name. In cosmetics it is one ingredient among many in serums and eye creams, usually at low percentages. In the research peptide market it is sold as a freeze-dried powder in vials, alongside injectable compounds such as BPC-157 and GHK-Cu. Everything known about SNAP-8 concerns the first product. Nothing in the published literature concerns the second. For how the research peptide market works, see what research peptides are.

Expression lines form because facial muscles contract repeatedly under the skin. Botulinum toxin type A smooths them by cutting SNAP-25 inside nerve endings, which stops the SNARE complex assembling and stops the nerve releasing acetylcholine onto the muscle. Argireline and SNAP-8 are designed to compete with the intact SNAP-25 protein for a place in that complex, so that fewer functional complexes form and the nerve releases less transmitter ^[1].

The idea that fragments of SNAP-25 can interfere with release is supported by neuroscience work that has nothing to do with cosmetics. A 2003 study showed that truncated SNAP-25 products, mimicking what botulinum toxins leave behind, inhibited glutamate release from rat hippocampal neurons and depressed synaptic transmission in Aplysia neurons, apparently by competing with the cell’s own SNAP-25 for binding to other SNARE proteins ^[3]. In the 2002 Argireline paper, the hexapeptide inhibited neurotransmitter release from cultured cells with a potency similar to botulinum toxin A but, as the authors noted, far lower efficacy ^[1].

The gap between that mechanism and a real face is the skin barrier. To act on a nerve ending, a hydrophilic peptide with a molecular weight over 1000 g/mol has to cross the stratum corneum and reach the neuromuscular junction, which sits in muscle below the dermis. A 2015 study from the US FDA’s own laboratories measured how much acetyl hexapeptide-8, the shorter parent peptide, penetrated human cadaver skin from a 10% oil-in-water emulsion over 24 hours: most was washed off the surface, about 0.22% of the dose stayed in the stratum corneum, and only about 0.01% reached the epidermis ^[6]. SNAP-8 is larger than Argireline, so there is no reason to expect it to penetrate better. Whether the tiny fraction that gets in is enough to affect nerve signalling is not known, and it is one reason some dermatologists doubt that the botulinum-like mechanism is what any measured effect actually reflects.

The claimed SNAP-8 benefits are a reduction in the depth of expression lines, especially crow’s feet and forehead lines, a smoothing of skin texture, and, in marketing aimed at people who dislike needles, a botox-like effect without injections. Searches for SNAP-8 vs Botox and SNAP-8 vs Argireline reflect those claims. Here is what the published record supports.

Argireline, the parent peptide, has the best data. In the original 2002 report, an emulsion containing 10% of the hexapeptide reduced wrinkle depth by up to 30% after 30 days in healthy women, measured by skin topography ^[1]. A 2013 randomised, placebo-controlled study in 60 Chinese subjects applied Argireline or placebo to peri-orbital wrinkles twice daily for four weeks: the subjective anti-wrinkle response rate was 48.9% with Argireline against 0% with placebo, and silicone replicas showed reduced roughness only in the treated group ^[2]. A 2023 double-blind trial in 21 Indonesian women compared acetyl hexapeptide-3 cream, palmitoyl pentapeptide-4 cream and placebo on crow’s feet over eight weeks; both peptides produced improvements in some subjects, but the pentapeptide did better than the hexapeptide, and the authors called it an initial study needing larger numbers ^[10]. Public interest in Argireline rose sharply in 2022 under the phrase “Botox in a bottle”, according to a 2024 analysis of search data ^[11].

SNAP-8 itself has no equivalent peer-reviewed trial. The manufacturer’s technical literature reports a wrinkle-depth reduction of roughly 35% after 28 days of a 10% SNAP-8 gel, a figure repeated on many product pages, but it comes from the seller’s own dossier and has not been independently published. The peer-reviewed human data on SNAP-8 come from two studies of dissolving microneedle patches in which acetyl octapeptide-3 was one of several actives. In a 2020 12-week study, hyaluronic acid microneedle patches containing acetyl octapeptide-3, palmitoyl tripeptide-5, an arginine/lysine polypeptide, adenosine and seaweed extracts were applied beside the eyes and on the forearm; fine lines decreased by 25.8%, hydration improved by 15.4% and dermal density and thickness rose by 14.2% and 12.9% ^[5]. In a 2024 split-face study in 24 healthy subjects, an overnight patch containing acetyl octapeptide-3, ascorbic acid 2-glucoside and cyclic lysophosphatidic acid improved eye wrinkles, water loss and elasticity over 28 days compared with a hyaluronic acid placebo patch ^[4]. In neither study can the effect be attributed to SNAP-8, because the patches contained other actives and, in the first, no placebo at all.

In short: the parent peptide has modest, short-term evidence for smoothing fine lines when applied topically; SNAP-8 is assumed to share it but has not been tested on its own in a published trial. The comparison with botulinum toxin is not supported by any head-to-head study, and given the penetration data it is unlikely that a cream reaches the muscle in the way an injection does.

There is no registered clinical trial of SNAP-8 or acetyl octapeptide-3 as of September 2026. The two human studies of patches containing it are described above ^{[4] [5]}. Both were small, both used products with several actives, and both were industry-linked.

The closest thing to a medical trial of this peptide family used Argireline, not SNAP-8. A randomised, triple-masked study of acetyl hexapeptide-8 in 24 patients with blepharospasm, an involuntary eyelid spasm usually treated with botulinum toxin injections, was registered in 2009 and listed as completed ^[13]. A second placebo-controlled study, started in 2012, was terminated after enrolling eight patients ^[14]. We found no published results from either, which is itself informative: if a topical SNARE-mimicking peptide had produced a clear muscle-relaxing effect, it would probably have been reported.

The remaining literature on Argireline concerns formulation, stability and analysis rather than efficacy. A 2021 analytical study found the peptide and its oxidised form in commercial creams and identified its methionine residue as the point of oxidation, raising a question about shelf life in finished products ^[9]. SNAP-8 contains the same methionine and is likely to be oxidised in the same way.

In the Argireline trials, differences from placebo were measured after four weeks of twice-daily application ^[2], and the original report described results at 30 days ^[1]. The microneedle patch studies with acetyl octapeptide-3 measured changes at 28 days and 12 weeks ^{[4] [5]}. There are no data on what happens after stopping, and no study has looked at use beyond three months. Because the proposed mechanism is a reversible reduction in nerve signalling rather than a structural change in the skin, any effect would be expected to fade once application stops, but that has not been measured.

SNAP-8 dosage is a question about topical concentration, not about milligrams injected. The original Argireline work used a 10% emulsion ^[1], and the FDA penetration study used the same 10% strength ^[6]. Commercial serums typically contain far less; the manufacturer’s recommended use level for SNAP-8 is in the range of 3 to 10%, and finished products rarely state the percentage. The patch studies did not report the amount of acetyl octapeptide-3 per patch ^{[4] [5]}.

No published study has given SNAP-8 by injection, by mouth or under the skin at any dose, so there is no dose for injected SNAP-8 to report. Research stores sell vials of 10 mg or more with no published basis for that quantity. The peptide calculator converts vial contents to concentration for laboratory work, but the absence of a studied dose is the point: none of these figures are recommendations, and there is nothing to calculate from.

Every published study of SNAP-8 or its parent applied it to the skin, as an emulsion, a serum or a dissolving microneedle patch. Microneedles are worth a note: a 2014 study on excised human skin found that microneedle pre-treatment increased the delivery of small cosmetic peptides by 2 to 22 fold, which is why patch formats have become the preferred way to test peptides that otherwise sit on the surface ^[12].

Research peptide suppliers sell SNAP-8 as lyophilised powder, often in the same 5 mg and 10 mg vials as injectable peptides, and some list it under a “cosmetic peptides” heading beside Pal-GHK, AHK-Cu and Matrixyl. Such vials can be dissolved into a home-made serum, which is at least consistent with the published route, though the peptide will not be stabilised against oxidation the way a formulated product is ^[9]. Injecting a peptide designed to block neurotransmitter release into the face is a different matter. A 2021 case report described a 45-year-old woman who developed erythema, nodules and abscesses at the injection sites a week after Argireline was injected into her forehead and temples; cultures grew Mycobacterium abscessus and she needed five months of antibiotics ^[7]. That was a contamination problem rather than a peptide effect, but it shows what injecting cosmetic peptides outside a clinical setting can lead to.

In the topical studies, SNAP-8 side effects were not a feature: the 12-week patch study reported no primary or cumulative skin reactions ^[5], the 2024 patch study reported no adverse effects ^[4], and the Argireline trials described the peptide as well tolerated, with the original paper reporting no oral toxicity or primary irritation at high doses in animals ^{[1] [2]}. The FDA penetration study was itself prompted by a regulatory concern that a peptide claimed to alter nerve signalling might reach deeper tissue; its finding that almost none does is reassuring for topical use and, at the same time, undermines the claimed mechanism ^[6].

Beyond that, the honest position is that safety has been assessed only for small amounts on the skin over a few weeks. Nobody has studied what SNAP-8 does if injected, whether it affects muscle function when it does reach a nerve ending, or what long-term use does. A 2026 paper on a safety-evaluation framework for cosmetic peptides notes that the industry is moving from animal studies to bioinformatic screening for toxin and allergen similarity, and that peptides with homology to human proteins generally raise fewer flags; a SNAP-25 fragment is in that category, but the framework is a screening tool, not a clinical safety record ^[15].

Two practical points follow from the chemistry. SNAP-8 contains methionine, which oxidises in finished products ^[9], so a vial reconstituted at home and kept for weeks is likely to lose potency. And the injection case report is a reminder that sterility, not the peptide, is the first hazard of injecting a cosmetic ingredient ^[7].

SNAP-8 is a cosmetic ingredient, not an approved medicine, in every market we cover. As acetyl octapeptide-3 it can be used in cosmetics in the UK, EU and US within the ordinary rules for cosmetic products, which do not require efficacy to be proven, only safety to be substantiated by the company placing the product on the market. It has no marketing authorisation as a drug anywhere, has not been considered by the FDA’s compounding programme, and does not appear on the WADA Prohibited List.

Sold as a “research chemical” in a vial, it falls under the general rules for research peptides rather than cosmetics law. Our legal status overview explains the position, with country pages for the UK and the US.

Lyophilised SNAP-8 is stored cold, dry and away from light, like other peptides; see how to store peptides. Because of its methionine residue, oxidation is the main degradation route once it is in solution ^[9], so reconstituted material should be kept refrigerated and used quickly. For laboratory reconstitution, bacteriostatic water is the usual solvent; in a home-made serum the peptide will be less stable than in a commercially formulated product with antioxidants and preservatives.

SNAP-8 is inexpensive to make relative to longer peptides, and prices vary widely between stores. Compare SNAP-8 prices across suppliers, and check listings in the UK and the US. Because there is no dosing study, price per milligram is the only meaningful comparison; see peptide prices explained.

A certificate of analysis for SNAP-8 should show a measured mass close to 1075 g/mol and a purity figure from HPLC; a mass of about 1091 g/mol would indicate the oxidised methionine form. Our guide to reading a COA explains what to look for, and our list of third-party tested suppliers shows which stores publish independent testing. Anyone buying SNAP-8 for a cosmetic formulation rather than injection should note that finished cosmetic products are made with the same ingredient and are tested for stability and preservation, which a vial is not.